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Background: Association between hepatitis B 
infection and chronic kidney disease is multi-
factorial. Hepatitis B infection has calamitous effects 
on health of dialysis patients as compared to general 
population and this study is conducted to determine 
the proportion of non-vaccinated patients who 
became HBV positive within 7 years of initiation of 
haemodialysis and also to determine frequencies of 
various risk factors of Hepatitis B in these patients.  
Methods: This descriptive cross sectional study 
was conducted at three tertiary care hospitals of 
Rawalpindi from May-September 2016. The study 
participants were 65 known cases of chronic kidney 
failure undergoing haemodialysis on regular basis 
who were confirmed to be HBV negative at the start 
of dialysis or within 6 months of initiation of 
dialysis. All the relevant information was taken from 
the records as well as by interviewing the patients 
and recorded in the structured checklist. Data was 
then analysed in SPSS and prevalence of HBV and 
associated risk factors were determined in these 
patients. 
Results: Out of 65 patients, only 1 patient (1.5%) 
had become HBV positive whereas remaining 64 
(98.5%) had remained HBV negative. The duration in 
months in this patient to become HBV positive was 
32 months. Smoking 14 (21.53%), Diabetes 16 
(24.61%), Hypertension 11 (16.92%) and Blood 
transfusion 15 (23.07%)  were the common risk 
factors observed in all patients while the only risk 
factor present in HBV positive patient was 
hypertension. 
Conclusion: Prevalence of Hepatitis B in non-
vaccinated, haemodialysis patients was observed to 
be low while the common risk factors of Hepatitis B 
infection observed in dialysis patients were 
diabetes, hypertension and blood transfusions. 
Key Words: Chronic kidney failure, Hepatitis B, 
Haemodialysis. 
Introduction 
Hepatitis B is one of the significant widespread 
infections present all across the world. So far, it has 
affected 2 billion people worldwide 1 & 2.4% of 
healthy adults in Pakistan 2. Hepatitis B, an infection of 
liver is transmitted from one person to the other via 
blood and fluids & from mother to child at birth, has 
different serum markers (Hepatitis B surface antigen 
HbsAg, Hepatitis B pre-core antigen HbeAg, Hepatitis 
B core antigen HbcAg, Hepatitis B surface antibody 
HbsAb, Hepatitis B core antibody HbcAb, Hepatitis B 
pre-core antibody HbeAb); HbsAg is used for 
diagnostic purpose3. End stage renal disease is a 
severe decline in the renal function and definitive 
susceptibility to death, unless treated by 
haemodialysis or renal transplantation. Haemodialysis 
is the preferred method to treat advanced and 
permanent renal failure worldwide4. Seroconversion 
occurs when there is development of antibodies 
against HbsAg5.  Nowadays Hepatitis B infection is 
more frequent in haemodialysis patients worldwide 
owing to their immunocompromised state and 
vulnerability to nosocomial infections. Importance of 
HBV in clinical nephrology is frequently pronounced 
in areas with endemic infections e.g. South East Asia. 
Prevalence of HBV carriers among patients on dialysis 
varies from about 1% in US to more than 10% in Asian 
countries6. 
Hepatitis B vaccination is being done worldwide in 
haemodialysis patients. It has a vaccination schedule 
of 4 doses at 0, 1, 2 and 6 months  with 2 doses of 
20mcg/ml (Engerix B) with a success rate of 
89.65%7,8. Age, time on haemodialysis, serum 
albumin and protein catabolic rate did not affect the 
response to the vaccine. However HCV infection was 
found to reduce the effectiveness of vaccine in these 
patients9.  
According to an international study conducted in Gaza 
strip, Palestine, overall prevalence of HBV among 
haemodialysis patients in 4 haemodialysis centres 
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came out to be 8.1%10. Another international study 
performed in India that 5.5% of patients become 
positive for HBV infections during haemodialysis that 
was conducted in dialysis unit of Agartala Govt. 
Medical College, during Jan 2011 to June 201111. A 
research was also done in Karachi, Pakistan which 
brought the results that 18.3% patients became HBV 
positive after hemodialysis12. 
This study will attempt to determine the magnitude of 
Hepatitis B as well as risk factors in patients of chronic 
renal failure (CRF) undergoing haemodialysis, so that 
the relation of occurrence of this infection with the 
procedure of dialysis can be demonstrated. It will also 
be helpful in eliminating the deficiencies so that the 
percentage of patients being seroconverted to this 
infection can be reduced. The exact proportion of 
patients becoming Hepatitis B positive after 
haemodialysis is a significant figure, therefore the 
study also focuses on the risk factors that predispose 
to the development of Hepatitis B in CRF patients, so 
that it will aid in the eradication of this fatal infection 
along with ruling out the correlation of its aetiology to 
haemodialysis. 
This study is basically conducted to determine the 
proportion of patients who seroconverted to Hepatitis 
B within 5 years of initiation of haemodialysis 
presenting to dialysis unit of Holy Family Hospital 
(HFH), Benazir Bhutto Hospital (BBH) and District 
Headquarter Hospital (DHQ). 
Materials And Methods 
This descriptive cross sectional study conducted in 
Holy Family Hospital, Rawalpindi, Benazir Bhutto 
Hospital, Rawalpindi and District Headquarter 
Hospital, Rawalpindi from May 2016 to September 
2016. The study population comprised of all patients 
with chronic kidney failure who were admitted or 
presented to Outdoor patient of dialysis units on 
regular basis. Patients who were seronegative for 
Hepatitis B infection before the start of dialysis, 
irrespective of place of dialysis, were included. All the 
patients included were not vaccinated against 
Hepatitis B infection and all those patients who were 
Hepatitis B positive before the start of dialysis or 
within 6 months of initiation of dialysis that is 
incubation period of HBV or vaccinated against 
Hepatitis B or had done kidney transplant were 
excluded. These patients were not receiving dialysis 
exclusively from these three health care facilities and 
had history of undergoing health care facilities at 
various dialysis centres, other than the one from which 
they were selected for the study.  
Our minimally required sample size was 65 patients, 
which was calculated by using WHO Sample Size 
Calculator at confidence level 95%, absolute precision 
5% and anticipated population proportion 4.4%13. We 
selected these 65 patients by using non-consecutive 
random sampling out of which 34 were selected from 
Holy Family Hospital, 19 from Benazir Bhutto 
Hospital and 12 from District Headquarter Hospital, 
Rawalpindi. Data was collected by thoroughly 
observing patients record and also by interviewing 
them. HBV serology before the start of dialysis and 
after the dialysis, repeated every 6 month were also 
recorded. All the categorical variables like gender, 
seropositivity or seronegativity for hepatitis B, 
presence and absence of other risk factors of Hepatitis 
B etc., frequencies along with percentages were 
calculated. For continuous variables like age of patient, 
duration of illness in months and duration since 
initiation of dialysis in months; means along with 
standard deviations were calculated.  
 
Results 
A total of 65 patients were included in study amongst 
whom 44 (67.7%) were males and 21 (32.3%) were 
females. Mean age of study participants was 42.09 
(+13.85) years, mode of age was 28 years and median 
was 40 years. Youngest participant was 19 years old 
while the oldest was 75 years old with a range of 56 
years. Mean time since diagnosis of chronic renal 
failure in all 65 patients was 30.08 months (+18.48 
months). Mean duration in months since first dialysis 
performed was 22.09 months (+ 40.46 months). Patient 
with longest duration of receiving dialysis was 71 
months while the patient with shortest duration since 
initiation of dialysis was 6 months. Data was collected 
regarding number of dialysis received during last 2 
years and the mean was observed to be 137.85 
(+51.01). Regarding number of health care facilities 
from which patients were receiving dialysis, only 12 
(18.5%) patients were confined to only 1 health care 
facility whereas remaining 28 (81.5%) had received 
dialysis from multiple health care facilities.  
As regards the presence of risk factors of Hepatitis B 
distribution amongst all study participants presence of 
Smoking 14 (21.53%), Diabetes 16 (24.61%), 
Hypertension 11 (16.92%), Blood transfusion 15 
(23.07%)  and positive family history of Hepatitis B 5 
(7.69%) were observed. The gender wise distribution 
of these risk factors is displayed in (Figure I). In the 
single patient who was found to be seroconverted to 
Hepatitis B only had positive history of Hypertension.  
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Only 1 patient, male, 31 years old who was diagnosed 
as a case of chronic renal failure 51 months ago but 
shifted on dialysis 36 months ago and  became HBV 
positive after 32 months of initiation of dialysis. He 
received total of 192 number of dialysis during last 2 
years from 3 different health care facilities of 
Rawalpindi. Only risk factor present before the start of 
dialysis was hypertension. He was hypertensive from 
last 7 years. He was not smoker and diabetic and never 
received any kind of blood transfusion. Family history 
of hepatitis was also negative. So, the conversion rate 
was 1.5 %. 
 
 
Figure I. Presence of Risk factors of Hepatitis B 
infection according to gender groups in 65 patients. 
 
Discussion 
Hepatitis B infection is potentially lethal condition and 
noteworthy problem in Pakistan that substantially 
increases the risk of glomerular diseases especially 
glomerulonephritis. Others include membranous 
nephropathy, membranoproliferative glomerul-
onephritis, IgA nephropathy and focal segmental 
glomerulosclerosis6. The conversion rate in our study 
was 1.5% and it is lower than international studies 
conducted in Gaza strip, Palestine and India where 
prevalence came out to be 8.1%10, 5.5%11 respectively. 
A research was also done in Karachi, Pakistan which 
brought the results that 18.3% patients became HBV 
positive after haemodialysis and this result was also 
higher than that of our study12. The lower conversion 
rate in our hospitals may be due to better facilities of 
health care and adequate provision of Hepatitis B 
vaccination. Results can also be affected by our small 
sample size. 
We also ascertained factors contributing to 
development of Hepatitis B in dialysis patients and 
they were smoking, sharing of syringes and razors, 
diabetes, hypertension, blood transfusion and family 
history. Most common contributing factors found to be 
diabetes, blood transfusion, smoking and 
hypertension. Blood transfusion can be the source of 
transfer of infection if there is not proper screening of 
blood. But other factors like diabetes, smoking and 
hypertension appear to be associations which increase 
the risks of developing renal problems in these 
patients, as a result making these patients more 
vulnerable to develop Hepatitis B infections. 
Regardless of lower conversion rate due to adequate 
provision of Hepatitis B vaccination, there is still 
substantial need to create awareness among CRF 
patients to be vaccinated against Hepatitis B before 
their first dialysis, so that this conversion rate falls to 
0%. Moreover, avoidance and control of all the risk 
factors in time either through preventive measures or 
by strictly controlling them through appropriate 
treatment can certainly lessen the prevalence. 
The strength of our study is that it is the first study to 
be conducted in our setup and also included the risks 
and associated factors in our study which has 
elaborated the results. Another positive aspect is that 
we excluded the vaccinated patients which confines 
the study to non-vaccinated population and in this 
way helps to assess the quality of our health care 
facilities that can get further improved to attain 0% 
occurrence rates. 
Conclusion 
Prevalence of Hepatitis B in non-vaccinated 
haemodialysis patients was observed to be low while 
the common risk factors of Hepatitis B infection 
observed in dialysis patients were diabetes, 
hypertension and blood transfusions. 
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